Neonatal hemochromatosis: Difference between revisions

(Created page with "Neonatal hemochromatosis (NH) is a clinical syndrome of '''severe neonatal liver disease with extrahepatic iron deposition''' (siderosis).<ref name="Feldman2013">Feldman AG, Whitington PF. Neonatal hemochromatosis. ''J Clin Exp Hepatol''. 2013;3(4):313-320. doi:10.1016/j.jceh.2013.10.004</ref> Nearly all cases are caused by '''gestational alloimmune liver disease (GALD)''', a maternal-fetal alloimmune disorder in which maternal IgG antibodies cross the placenta, attack f...")
 
(Moved intro paragraph into Background as bullets; removed excessive bold from bullet lead-ins; bold retained for critical items only)
Line 1: Line 1:
Neonatal hemochromatosis (NH) is a clinical syndrome of '''severe neonatal liver disease with extrahepatic iron deposition''' (siderosis).<ref name="Feldman2013">Feldman AG, Whitington PF. Neonatal hemochromatosis. ''J Clin Exp Hepatol''. 2013;3(4):313-320. doi:10.1016/j.jceh.2013.10.004</ref> Nearly all cases are caused by '''gestational alloimmune liver disease (GALD)''', a maternal-fetal alloimmune disorder in which maternal IgG antibodies cross the placenta, attack fetal hepatocytes, and activate complement-mediated destruction.<ref name="Feldman2013"/> NH/GALD is the '''leading treatable cause of neonatal acute liver failure''' and carries '''>90% mortality without treatment'''.<ref name="AASLD">Little Livers, BIG Problems! Gestational Alloimmune Liver Disease. ''AASLD Liver Fellow Network''. 2024.</ref> The emergency physician must recognize the pattern of '''liver failure at birth with massively elevated ferritin and AFP''', initiate '''IVIG empirically''', and arrange '''double-volume exchange transfusion''' and urgent hepatology/neonatology consultation.
==Background==
==Background==
*'''Not a hereditary hemochromatosis''' — despite the name, NH is an alloimmune disease, not a genetic iron storage disorder<ref name="Feldman2013"/>
*Neonatal hemochromatosis (NH) is a clinical syndrome of severe neonatal liver disease with extrahepatic iron deposition (siderosis).<ref name="Feldman2013">Feldman AG, Whitington PF. Neonatal hemochromatosis. ''J Clin Exp Hepatol''. 2013;3(4):313-320. doi:10.1016/j.jceh.2013.10.004</ref> Nearly all cases are caused by gestational alloimmune liver disease (GALD), a maternal-fetal alloimmune disorder in which maternal IgG antibodies cross the placenta, attack fetal hepatocytes, and activate complement-mediated destruction.<ref name="Feldman2013"/> NH/GALD is the leading treatable cause of neonatal acute liver failure and carries >90% mortality without treatment.<ref name="AASLD">Little Livers, BIG Problems! Gestational Alloimmune Liver Disease. ''AASLD Liver Fellow Network''. 2024.</ref> The emergency physician must recognize the pattern of liver failure at birth with massively elevated ferritin and AFP, initiate IVIG empirically, and arrange double-volume exchange transfusion and urgent hepatology/neonatology consultation.
* Not a hereditary hemochromatosis — despite the name, NH is an alloimmune disease, not a genetic iron storage disorder<ref name="Feldman2013"/>
*Incidence: approximately 4 per 100,000 live births in the US; extremely rare globally (<1 per 1,000,000)
*Incidence: approximately 4 per 100,000 live births in the US; extremely rare globally (<1 per 1,000,000)
*GALD accounts for ~95% of NH cases<ref name="Stanford">Neonatal Hemochromatosis. ''Stanford Medicine Children's Health''. 2024.</ref>
*GALD accounts for ~95% of NH cases<ref name="Stanford">Neonatal Hemochromatosis. ''Stanford Medicine Children's Health''. 2024.</ref>
Line 17: Line 16:


===Recurrence risk===
===Recurrence risk===
*'''80-95% recurrence in subsequent pregnancies''' — this is critical information for family counseling<ref name="GALD_recon">Gestational alloimmune liver disease reconsidered. ''World J Gastroenterol''. 2025.</ref>
* 80-95% recurrence in subsequent pregnancies — this is critical information for family counseling<ref name="GALD_recon">Gestational alloimmune liver disease reconsidered. ''World J Gastroenterol''. 2025.</ref>
*Maternal '''IVIG during pregnancy''' (weekly from 18 weeks gestation) reduces recurrence to 5-10% with nearly 100% healthy live births<ref name="Stanford"/>
*Maternal '''IVIG during pregnancy''' (weekly from 18 weeks gestation) reduces recurrence to 5-10% with nearly 100% healthy live births<ref name="Stanford"/>
*First affected pregnancy is ''not'' predictable; typically unrecognized until the affected neonate presents
*First affected pregnancy is ''not'' predictable; typically unrecognized until the affected neonate presents
Line 24: Line 23:
===Presentation at birth or within hours===
===Presentation at birth or within hours===
*Most NH infants are symptomatic '''at birth or within the first hours of life''' — this distinguishes NH from most other causes of neonatal liver failure, which typically develop over days to weeks<ref name="Feldman2013"/>
*Most NH infants are symptomatic '''at birth or within the first hours of life''' — this distinguishes NH from most other causes of neonatal liver failure, which typically develop over days to weeks<ref name="Feldman2013"/>
*'''Liver failure at birth:'''
* Liver failure at birth:
**Severe '''conjugated hyperbilirubinemia''' (total bilirubin may exceed 30 mg/dL)
**Severe '''conjugated hyperbilirubinemia''' (total bilirubin may exceed 30 mg/dL)
**'''Profound coagulopathy''' (INR often >3; unresponsive to vitamin K)
** Profound coagulopathy (INR often >3; unresponsive to vitamin K)
**'''Hypoalbuminemia'''
** Hypoalbuminemia
**'''Hypoglycemia''' (impaired hepatic gluconeogenesis)
** Hypoglycemia (impaired hepatic gluconeogenesis)
**'''Hyperammonemia'''
** Hyperammonemia
*'''Ascites and edema'''
* Ascites and edema
*'''Hepatomegaly''' (liver palpable several cm below costal margin; may also be small if severe cirrhosis)
* Hepatomegaly (liver palpable several cm below costal margin; may also be small if severe cirrhosis)
*'''Oliguria/renal failure''' (hepatorenal syndrome)
* Oliguria/renal failure (hepatorenal syndrome)


===Prenatal findings (may be reported in history)===
===Prenatal findings (may be reported in history)===
*'''Intrauterine growth restriction (IUGR)'''
* Intrauterine growth restriction (IUGR)
*'''Oligohydramnios'''
* Oligohydramnios
*'''Hydrops fetalis''' (in severe cases)
* Hydrops fetalis (in severe cases)
*'''Stillbirth''' (NH should be considered in unexplained fetal demise)
* Stillbirth (NH should be considered in unexplained fetal demise)
*Prematurity (about half of NH infants are preterm)<ref name="Frontiers_GALD">Efficacy of IVIG/ET Therapy on GALD. ''Front Pediatr''. 2021;9:680730.</ref>
*Prematurity (about half of NH infants are preterm)<ref name="Frontiers_GALD">Efficacy of IVIG/ET Therapy on GALD. ''Front Pediatr''. 2021;9:680730.</ref>


===Characteristic laboratory pattern===
===Characteristic laboratory pattern===
The following constellation is highly suggestive of NH:
The following constellation is highly suggestive of NH:
*'''Ferritin: massively elevated''' (typically >800 ng/mL; commonly 2,000-150,000+ ng/mL) — sensitive but not specific, as any severe liver injury elevates ferritin<ref name="Feldman2013"/>
* Ferritin: massively elevated (typically >800 ng/mL; commonly 2,000-150,000+ ng/mL) — sensitive but not specific, as any severe liver injury elevates ferritin<ref name="Feldman2013"/>
*'''Transferrin: low but hypersaturated''' (saturation often >90-100%) — one of the most characteristic findings<ref name="Medscape_NH">Neonatal Hemochromatosis Workup. ''Medscape''. 2024.</ref>
* Transferrin: low but hypersaturated (saturation often >90-100%) — one of the most characteristic findings<ref name="Medscape_NH">Neonatal Hemochromatosis Workup. ''Medscape''. 2024.</ref>
*'''AFP: very high''' (typically 100,000-600,000 ng/mL — even higher than neonatal baseline)
* AFP: very high (typically 100,000-600,000 ng/mL — even higher than neonatal baseline)
*'''AST/ALT: disproportionately low''' (often <100 IU/L despite severe liver failure) — this is because there are so few viable hepatocytes remaining that transaminase release is minimal<ref name="Feldman2013"/>
* AST/ALT: disproportionately low (often <100 IU/L despite severe liver failure) — this is because there are so few viable hepatocytes remaining that transaminase release is minimal<ref name="Feldman2013"/>
*'''INR markedly elevated''' (often >3)
* INR markedly elevated (often >3)
*Hypoglycemia, hyperammonemia, hypoalbuminemia, metabolic acidosis
*Hypoglycemia, hyperammonemia, hypoalbuminemia, metabolic acidosis


==Differential diagnosis==
==Differential diagnosis==
===Neonatal acute liver failure===
===Neonatal acute liver failure===
*'''[[Neonatal HSV|Neonatal herpes simplex (HSV)]]''' — the most important alternative diagnosis; '''start empiric acyclovir''' alongside IVIG while differentiating (HSV typically presents slightly later, days 7-14, and has markedly elevated AST/ALT, unlike NH)
* [[Neonatal HSV|Neonatal herpes simplex (HSV)]] — the most important alternative diagnosis; '''start empiric acyclovir''' alongside IVIG while differentiating (HSV typically presents slightly later, days 7-14, and has markedly elevated AST/ALT, unlike NH)
*'''[[Tyrosinemia|Tyrosinemia type 1]]''' — very high AFP + coagulopathy (similar to NH); Fanconi syndrome distinguishes; urine succinylacetone is pathognomonic
* [[Tyrosinemia|Tyrosinemia type 1]] — very high AFP + coagulopathy (similar to NH); Fanconi syndrome distinguishes; urine succinylacetone is pathognomonic
*'''[[Galactosemia]]''' — after initiation of lactose-containing feeds; reducing substances in urine; ''E. coli'' sepsis
* [[Galactosemia]] — after initiation of lactose-containing feeds; reducing substances in urine; ''E. coli'' sepsis
*'''Hemophagocytic lymphohistiocytosis (HLH)''' — fever, hepatosplenomegaly, pancytopenia, hyperferritinemia, hypertriglyceridemia; can closely mimic NH; soluble IL-2 receptor and NK cell activity help distinguish
* Hemophagocytic lymphohistiocytosis (HLH) — fever, hepatosplenomegaly, pancytopenia, hyperferritinemia, hypertriglyceridemia; can closely mimic NH; soluble IL-2 receptor and NK cell activity help distinguish
*'''Hereditary fructose intolerance''' — after fructose/sucrose exposure
* Hereditary fructose intolerance — after fructose/sucrose exposure
*'''Mitochondrial hepatopathy''' (DGUOK mutations, others)
* Mitochondrial hepatopathy (DGUOK mutations, others)
*'''Bile acid synthesis defects'''
* Bile acid synthesis defects
*'''Bacterial [[Sepsis|sepsis]]'''
* Bacterial [[Sepsis|sepsis]]


===Key distinguishing features of NH===
===Key distinguishing features of NH===
*Liver failure '''present at or within hours of birth''' (most other causes present later)
*Liver failure '''present at or within hours of birth''' (most other causes present later)
*AST/ALT '''disproportionately low''' for degree of liver failure
*AST/ALT '''disproportionately low''' for degree of liver failure
*'''Extrahepatic siderosis''' (pancreas, heart, thyroid iron-laden on MRI) with '''splenic sparing'''
* Extrahepatic siderosis (pancreas, heart, thyroid iron-laden on MRI) with '''splenic sparing'''
*Ferritin and transferrin saturation massively elevated
*Ferritin and transferrin saturation massively elevated


==Evaluation==
==Evaluation==
===ED workup===
===ED workup===
*'''Hepatic panel:''' AST, ALT (expect disproportionately low), bilirubin (fractionate), albumin
* Hepatic panel: AST, ALT (expect disproportionately low), bilirubin (fractionate), albumin
*'''Coagulation studies:''' PT/INR, fibrinogen
* Coagulation studies: PT/INR, fibrinogen
*'''Ferritin:''' expect massively elevated (>800 ng/mL; commonly >10,000)
* Ferritin: expect massively elevated (>800 ng/mL; commonly >10,000)
*'''Iron studies:''' serum iron, transferrin, '''transferrin saturation''' (expect >90%)
* Iron studies: serum iron, transferrin, '''transferrin saturation''' (expect >90%)
*'''AFP (alpha-fetoprotein):''' expect markedly elevated
* AFP (alpha-fetoprotein): expect markedly elevated
*'''Blood glucose:''' frequent monitoring; anticipate hypoglycemia
* Blood glucose: frequent monitoring; anticipate hypoglycemia
*'''Ammonia'''
* Ammonia
*'''BMP:''' electrolytes, creatinine (hepatorenal syndrome)
* BMP: electrolytes, creatinine (hepatorenal syndrome)
*'''CBC:''' thrombocytopenia (common)
* CBC: thrombocytopenia (common)
*'''Blood cultures, urinalysis/urine culture''' — to exclude sepsis
* Blood cultures, urinalysis/urine culture — to exclude sepsis
*'''HSV PCR''' (blood and CSF if LP feasible) — '''must exclude HSV empirically'''
* HSV PCR (blood and CSF if LP feasible) — '''must exclude HSV empirically'''
*'''Lactate'''
* Lactate


===Confirmatory testing for extrahepatic siderosis===
===Confirmatory testing for extrahepatic siderosis===
*'''Abdominal MRI (T2-weighted):''' the most useful diagnostic study<ref name="Medscape_NH"/>
* Abdominal MRI (T2-weighted): the most useful diagnostic study<ref name="Medscape_NH"/>
**Demonstrates '''low T2 signal in liver and pancreas''' (iron-laden) with '''normal/preserved signal in spleen''' (reticuloendothelial sparing)
**Demonstrates '''low T2 signal in liver and pancreas''' (iron-laden) with '''normal/preserved signal in spleen''' (reticuloendothelial sparing)
**Can also show iron in myocardium and thyroid
**Can also show iron in myocardium and thyroid
**'''Extrahepatic siderosis in pancreas + thyroid is diagnostic''' of NH
** Extrahepatic siderosis in pancreas + thyroid is diagnostic of NH
**Can be performed within hours of birth
**Can be performed within hours of birth
*'''Buccal (minor salivary gland) biopsy:'''<ref name="Feldman2013"/>
* Buccal (minor salivary gland) biopsy:<ref name="Feldman2013"/>
**3-mm punch biopsy of lower lip mucosa (must include submucosal salivary glands)
**3-mm punch biopsy of lower lip mucosa (must include submucosal salivary glands)
**Prussian blue stain reveals hemosiderin in acinar epithelial cells
**Prussian blue stain reveals hemosiderin in acinar epithelial cells
**Positive in approximately two-thirds of proven NH cases
**Positive in approximately two-thirds of proven NH cases
**Minimally invasive; can be performed at bedside even with severe coagulopathy (bleeding controlled by local measures; FFP not required beforehand)
**Minimally invasive; can be performed at bedside even with severe coagulopathy (bleeding controlled by local measures; FFP not required beforehand)
*'''Liver biopsy:''' generally '''avoided''' due to severe coagulopathy; if performed, shows hepatocyte loss, giant cell transformation, fibrosis/cirrhosis, hepatocyte siderosis with Kupffer cell sparing; C5b-9 immunostaining supports GALD diagnosis
* Liver biopsy: generally '''avoided''' due to severe coagulopathy; if performed, shows hepatocyte loss, giant cell transformation, fibrosis/cirrhosis, hepatocyte siderosis with Kupffer cell sparing; C5b-9 immunostaining supports GALD diagnosis
*If either MRI or buccal biopsy demonstrates extrahepatic siderosis → '''diagnosis of NH is established'''<ref name="Feldman2013"/>
*If either MRI or buccal biopsy demonstrates extrahepatic siderosis → '''diagnosis of NH is established'''<ref name="Feldman2013"/>


==Management==
==Management==
===Immediate ED management===
===Immediate ED management===
*'''Give one dose of IVIG (1 g/kg IV)''' as soon as NH/GALD is suspected — '''do not wait for MRI or biopsy confirmation'''<ref name="AASLD"/>
* Give one dose of IVIG (1 g/kg IV) as soon as NH/GALD is suspected — '''do not wait for MRI or biopsy confirmation'''<ref name="AASLD"/>
**Mechanism: blocks complement-activating antibodies from continuing hepatocyte destruction
**Mechanism: blocks complement-activating antibodies from continuing hepatocyte destruction
**Current expert recommendation: any neonate in liver failure should receive one dose of IVIG while GALD is being evaluated<ref name="Feldman2013"/>
**Current expert recommendation: any neonate in liver failure should receive one dose of IVIG while GALD is being evaluated<ref name="Feldman2013"/>
*'''Start empiric IV acyclovir''' (20 mg/kg/dose every 8 hours) simultaneously — HSV disseminated disease is the most important alternative diagnosis and cannot be reliably excluded clinically; treat for both until testing clarifies
* Start empiric IV acyclovir (20 mg/kg/dose every 8 hours) simultaneously — HSV disseminated disease is the most important alternative diagnosis and cannot be reliably excluded clinically; treat for both until testing clarifies
*'''Correct coagulopathy:''' FFP, cryoprecipitate (note: coagulopathy in NH is often '''refractory to vitamin K''' because it reflects synthetic failure, not vitamin K deficiency)
* Correct coagulopathy: FFP, cryoprecipitate (note: coagulopathy in NH is often '''refractory to vitamin K''' because it reflects synthetic failure, not vitamin K deficiency)
*'''Correct hypoglycemia:''' D10W infusion with frequent glucose monitoring
* Correct hypoglycemia: D10W infusion with frequent glucose monitoring
*'''IV fluids:''' cautious volume management (risk of fluid overload with ascites/edema)
* IV fluids: cautious volume management (risk of fluid overload with ascites/edema)
*'''Broad-spectrum antibiotics''' if sepsis is in the differential
* Broad-spectrum antibiotics if sepsis is in the differential


===Definitive treatment===
===Definitive treatment===
*'''Double-volume exchange transfusion (DVET):'''<ref name="GALD_case">Gestational alloimmune liver disease treated with exchange transfusion and IVIG. ''Pediatr Neonatol''. 2022;63(1):94-96.</ref>
* Double-volume exchange transfusion (DVET):<ref name="GALD_case">Gestational alloimmune liver disease treated with exchange transfusion and IVIG. ''Pediatr Neonatol''. 2022;63(1):94-96.</ref>
**Purpose: physically removes circulating maternal IgG antibodies that are driving hepatocyte destruction
**Purpose: physically removes circulating maternal IgG antibodies that are driving hepatocyte destruction
**Performed with '''twice the calculated blood volume'''
**Performed with '''twice the calculated blood volume'''
**Should be followed immediately by IVIG infusion
**Should be followed immediately by IVIG infusion
*'''IVIG (1 g/kg IV):''' given after DVET to block any remaining antibody-induced complement activation
* IVIG (1 g/kg IV): given after DVET to block any remaining antibody-induced complement activation
**May require multiple doses (published cases describe 1-4 doses)
**May require multiple doses (published cases describe 1-4 doses)
*This combination (DVET + IVIG) has improved survival from ~10-20% (historical) to '''75%''' without liver transplant in the best-reported series<ref name="Feldman2013"/>
*This combination (DVET + IVIG) has improved survival from ~10-20% (historical) to '''75%''' without liver transplant in the best-reported series<ref name="Feldman2013"/>
Line 123: Line 122:


===Therapies of historical interest (largely replaced)===
===Therapies of historical interest (largely replaced)===
*'''Antioxidant/chelation cocktail''' (vitamin E, selenium, N-acetylcysteine, prostaglandin E1, deferoxamine) — used before GALD mechanism was discovered; survival only 10-20%; no longer first-line<ref name="Feldman2013"/>
* Antioxidant/chelation cocktail (vitamin E, selenium, N-acetylcysteine, prostaglandin E1, deferoxamine) — used before GALD mechanism was discovered; survival only 10-20%; no longer first-line<ref name="Feldman2013"/>


==Disposition==
==Disposition==
*'''All suspected NH cases: NICU admission'''
* All suspected NH cases: NICU admission
*'''Immediate consultations:'''
* Immediate consultations:
**Neonatology (DVET, NICU management)
**Neonatology (DVET, NICU management)
**Pediatric hepatology/GI (diagnosis confirmation, IVIG, transplant evaluation)
**Pediatric hepatology/GI (diagnosis confirmation, IVIG, transplant evaluation)
**Pediatric surgery/transplant center (early notification — emergent transplant may be needed)
**Pediatric surgery/transplant center (early notification — emergent transplant may be needed)
*'''Transfer to a center with neonatal liver transplant capability''' if not available locally — do not delay IVIG while arranging transfer
* Transfer to a center with neonatal liver transplant capability if not available locally — do not delay IVIG while arranging transfer
*'''Communicate to the family:'''
* Communicate to the family:
**90% recurrence risk in future pregnancies
**90% recurrence risk in future pregnancies
**Prenatal IVIG treatment is available and highly effective for preventing recurrence
**Prenatal IVIG treatment is available and highly effective for preventing recurrence

Revision as of 14:15, 19 March 2026

Background

  • Neonatal hemochromatosis (NH) is a clinical syndrome of severe neonatal liver disease with extrahepatic iron deposition (siderosis).[1] Nearly all cases are caused by gestational alloimmune liver disease (GALD), a maternal-fetal alloimmune disorder in which maternal IgG antibodies cross the placenta, attack fetal hepatocytes, and activate complement-mediated destruction.[1] NH/GALD is the leading treatable cause of neonatal acute liver failure and carries >90% mortality without treatment.[2] The emergency physician must recognize the pattern of liver failure at birth with massively elevated ferritin and AFP, initiate IVIG empirically, and arrange double-volume exchange transfusion and urgent hepatology/neonatology consultation.
  • Not a hereditary hemochromatosis — despite the name, NH is an alloimmune disease, not a genetic iron storage disorder[1]
  • Incidence: approximately 4 per 100,000 live births in the US; extremely rare globally (<1 per 1,000,000)
  • GALD accounts for ~95% of NH cases[3]

Mechanism

  • Mother becomes sensitized to a fetal hepatocyte surface antigen (the specific antigen remains unidentified)
  • Maternal IgG antibodies cross the placenta (actively transported from ~18 weeks gestation)
  • IgG binds fetal hepatocytes → activates terminal complement cascade (C5b-9) → hepatocyte injury and death[1]
  • Massive hepatocyte loss → liver failure, congenital cirrhosis
  • Secondary iron overload occurs because:
    • Damaged hepatocytes release stored iron
    • Impaired hepatic hepcidin production → unregulated iron absorption
    • Iron deposits in extrahepatic organs (pancreas, myocardium, thyroid, salivary glands) in a pattern that spares the reticuloendothelial system (spleen, lymph nodes, bone marrow are not iron-laden — this distinguishes NH from transfusional iron overload)[1]

Recurrence risk

  • 80-95% recurrence in subsequent pregnancies — this is critical information for family counseling[4]
  • Maternal IVIG during pregnancy (weekly from 18 weeks gestation) reduces recurrence to 5-10% with nearly 100% healthy live births[3]
  • First affected pregnancy is not predictable; typically unrecognized until the affected neonate presents

Clinical features

Presentation at birth or within hours

  • Most NH infants are symptomatic at birth or within the first hours of life — this distinguishes NH from most other causes of neonatal liver failure, which typically develop over days to weeks[1]
  • Liver failure at birth:
    • Severe conjugated hyperbilirubinemia (total bilirubin may exceed 30 mg/dL)
    • Profound coagulopathy (INR often >3; unresponsive to vitamin K)
    • Hypoalbuminemia
    • Hypoglycemia (impaired hepatic gluconeogenesis)
    • Hyperammonemia
  • Ascites and edema
  • Hepatomegaly (liver palpable several cm below costal margin; may also be small if severe cirrhosis)
  • Oliguria/renal failure (hepatorenal syndrome)

Prenatal findings (may be reported in history)

  • Intrauterine growth restriction (IUGR)
  • Oligohydramnios
  • Hydrops fetalis (in severe cases)
  • Stillbirth (NH should be considered in unexplained fetal demise)
  • Prematurity (about half of NH infants are preterm)[5]

Characteristic laboratory pattern

The following constellation is highly suggestive of NH:

  • Ferritin: massively elevated (typically >800 ng/mL; commonly 2,000-150,000+ ng/mL) — sensitive but not specific, as any severe liver injury elevates ferritin[1]
  • Transferrin: low but hypersaturated (saturation often >90-100%) — one of the most characteristic findings[6]
  • AFP: very high (typically 100,000-600,000 ng/mL — even higher than neonatal baseline)
  • AST/ALT: disproportionately low (often <100 IU/L despite severe liver failure) — this is because there are so few viable hepatocytes remaining that transaminase release is minimal[1]
  • INR markedly elevated (often >3)
  • Hypoglycemia, hyperammonemia, hypoalbuminemia, metabolic acidosis

Differential diagnosis

Neonatal acute liver failure

  • Neonatal herpes simplex (HSV) — the most important alternative diagnosis; start empiric acyclovir alongside IVIG while differentiating (HSV typically presents slightly later, days 7-14, and has markedly elevated AST/ALT, unlike NH)
  • Tyrosinemia type 1 — very high AFP + coagulopathy (similar to NH); Fanconi syndrome distinguishes; urine succinylacetone is pathognomonic
  • Galactosemia — after initiation of lactose-containing feeds; reducing substances in urine; E. coli sepsis
  • Hemophagocytic lymphohistiocytosis (HLH) — fever, hepatosplenomegaly, pancytopenia, hyperferritinemia, hypertriglyceridemia; can closely mimic NH; soluble IL-2 receptor and NK cell activity help distinguish
  • Hereditary fructose intolerance — after fructose/sucrose exposure
  • Mitochondrial hepatopathy (DGUOK mutations, others)
  • Bile acid synthesis defects
  • Bacterial sepsis

Key distinguishing features of NH

  • Liver failure present at or within hours of birth (most other causes present later)
  • AST/ALT disproportionately low for degree of liver failure
  • Extrahepatic siderosis (pancreas, heart, thyroid iron-laden on MRI) with splenic sparing
  • Ferritin and transferrin saturation massively elevated

Evaluation

ED workup

  • Hepatic panel: AST, ALT (expect disproportionately low), bilirubin (fractionate), albumin
  • Coagulation studies: PT/INR, fibrinogen
  • Ferritin: expect massively elevated (>800 ng/mL; commonly >10,000)
  • Iron studies: serum iron, transferrin, transferrin saturation (expect >90%)
  • AFP (alpha-fetoprotein): expect markedly elevated
  • Blood glucose: frequent monitoring; anticipate hypoglycemia
  • Ammonia
  • BMP: electrolytes, creatinine (hepatorenal syndrome)
  • CBC: thrombocytopenia (common)
  • Blood cultures, urinalysis/urine culture — to exclude sepsis
  • HSV PCR (blood and CSF if LP feasible) — must exclude HSV empirically
  • Lactate

Confirmatory testing for extrahepatic siderosis

  • Abdominal MRI (T2-weighted): the most useful diagnostic study[6]
    • Demonstrates low T2 signal in liver and pancreas (iron-laden) with normal/preserved signal in spleen (reticuloendothelial sparing)
    • Can also show iron in myocardium and thyroid
    • Extrahepatic siderosis in pancreas + thyroid is diagnostic of NH
    • Can be performed within hours of birth
  • Buccal (minor salivary gland) biopsy:[1]
    • 3-mm punch biopsy of lower lip mucosa (must include submucosal salivary glands)
    • Prussian blue stain reveals hemosiderin in acinar epithelial cells
    • Positive in approximately two-thirds of proven NH cases
    • Minimally invasive; can be performed at bedside even with severe coagulopathy (bleeding controlled by local measures; FFP not required beforehand)
  • Liver biopsy: generally avoided due to severe coagulopathy; if performed, shows hepatocyte loss, giant cell transformation, fibrosis/cirrhosis, hepatocyte siderosis with Kupffer cell sparing; C5b-9 immunostaining supports GALD diagnosis
  • If either MRI or buccal biopsy demonstrates extrahepatic siderosis → diagnosis of NH is established[1]

Management

Immediate ED management

  • Give one dose of IVIG (1 g/kg IV) as soon as NH/GALD is suspected — do not wait for MRI or biopsy confirmation[2]
    • Mechanism: blocks complement-activating antibodies from continuing hepatocyte destruction
    • Current expert recommendation: any neonate in liver failure should receive one dose of IVIG while GALD is being evaluated[1]
  • Start empiric IV acyclovir (20 mg/kg/dose every 8 hours) simultaneously — HSV disseminated disease is the most important alternative diagnosis and cannot be reliably excluded clinically; treat for both until testing clarifies
  • Correct coagulopathy: FFP, cryoprecipitate (note: coagulopathy in NH is often refractory to vitamin K because it reflects synthetic failure, not vitamin K deficiency)
  • Correct hypoglycemia: D10W infusion with frequent glucose monitoring
  • IV fluids: cautious volume management (risk of fluid overload with ascites/edema)
  • Broad-spectrum antibiotics if sepsis is in the differential

Definitive treatment

  • Double-volume exchange transfusion (DVET):[7]
    • Purpose: physically removes circulating maternal IgG antibodies that are driving hepatocyte destruction
    • Performed with twice the calculated blood volume
    • Should be followed immediately by IVIG infusion
  • IVIG (1 g/kg IV): given after DVET to block any remaining antibody-induced complement activation
    • May require multiple doses (published cases describe 1-4 doses)
  • This combination (DVET + IVIG) has improved survival from ~10-20% (historical) to 75% without liver transplant in the best-reported series[1]
  • Do NOT give mother's breast milk — maternal antibodies directed against neonatal hepatocytes may continue to pass through breast milk[2]

Liver transplant

  • Consider if patient fails to respond to IVIG ± DVET within days
  • NH is a common indication for liver transplantation in the first 3 months of life
  • INR recovery may take 4-6 weeks or longer after successful immunotherapy — treatment prevents ongoing immune injury but does not reverse damage already sustained[2]

Therapies of historical interest (largely replaced)

  • Antioxidant/chelation cocktail (vitamin E, selenium, N-acetylcysteine, prostaglandin E1, deferoxamine) — used before GALD mechanism was discovered; survival only 10-20%; no longer first-line[1]

Disposition

  • All suspected NH cases: NICU admission
  • Immediate consultations:
    • Neonatology (DVET, NICU management)
    • Pediatric hepatology/GI (diagnosis confirmation, IVIG, transplant evaluation)
    • Pediatric surgery/transplant center (early notification — emergent transplant may be needed)
  • Transfer to a center with neonatal liver transplant capability if not available locally — do not delay IVIG while arranging transfer
  • Communicate to the family:
    • 90% recurrence risk in future pregnancies
    • Prenatal IVIG treatment is available and highly effective for preventing recurrence
    • Refer to maternal-fetal medicine for future pregnancy planning

See Also

External Links

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 Feldman AG, Whitington PF. Neonatal hemochromatosis. J Clin Exp Hepatol. 2013;3(4):313-320. doi:10.1016/j.jceh.2013.10.004
  2. ↑ 2.0 2.1 2.2 2.3 Little Livers, BIG Problems! Gestational Alloimmune Liver Disease. AASLD Liver Fellow Network. 2024.
  3. ↑ 3.0 3.1 Neonatal Hemochromatosis. Stanford Medicine Children's Health. 2024.
  4. ↑ Gestational alloimmune liver disease reconsidered. World J Gastroenterol. 2025.
  5. ↑ Efficacy of IVIG/ET Therapy on GALD. Front Pediatr. 2021;9:680730.
  6. ↑ 6.0 6.1 Neonatal Hemochromatosis Workup. Medscape. 2024.
  7. ↑ Gestational alloimmune liver disease treated with exchange transfusion and IVIG. Pediatr Neonatol. 2022;63(1):94-96.
Retrieved from "https://www.wikem.org/w/index.php?title=Neonatal_hemochromatosis&oldid=386204"